Gene · 6582
Papers2,540
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,540
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Effects of Cimetidine and Dolutegravir on the Endogenous Drug-Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers. | Clin Pharmacol Ther | 2025 | 39497599 | PubTator, text mining | PubMed |
| Doxepin as OCT2 inhibitor ameliorates inflammatory response and modulates PI3K/Akt signaling associated with cisplatin-induced nephrotoxicity in rats. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | 39400714 | PubTator, text mining | PubMed |
| New Biomarkers for Renal Transporter-Mediated Drug-Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans. | Clin Pharmacol Ther | 2025 | 39148267 | PubTator, text mining | PubMed |
| Genetic variation on dolutegravir pharmacokinetics and relation to safety and efficacy outcomes: a systematic review. | Pharmacogenomics | 2024 | 39697075 | PubTator, text mining | PubMed |
| Allele frequencies and genotype distribution of three metformin transporter polymorphisms in Mexican population and their application in pharmacogenomics of type 2 diabetes. | Front Pharmacol | 2024 | 39555090 | PubTator, text mining | PubMed |
| Longitudinal assessment of SNPs rs72552763 and rs622342 in SLC22A1 over HbA1c control among Mexican-Mestizo diabetic type 2 patients. | Front Pharmacol | 2024 | 39403148 | PubTator, text mining | PubMed |
| Pharmacogenetic analysis of structural variation in the 1000 genomes project using whole genome sequences. | Sci Rep | 2024 | 39354004 | PubTator, text mining | PubMed |
| Efficient proximal tubule-on-chip model from hiPSC-derived kidney organoids for functional analysis of renal transporters. | iScience | 2024 | 39286490 | PubTator, text mining | PubMed |
| Mitochondrial related variants associated with cardiovascular traits. | Front Physiol | 2024 | 39258111 | PubTator, text mining | PubMed |
| Identification of human-specific amino acid residues governing atenolol transport via organic cation transporter 2. | Biochem Pharmacol | 2024 | 39236937 | PubTator, text mining | PubMed |
| Bioenergetics disruption, oxidative stress, and inflammation as underlying mechanisms of tramadol-induced nephrotoxicity. | J Biochem Mol Toxicol | 2024 | 39165170 | PubTator, text mining | PubMed |
| Proton Pump Inhibitors May Cause a Decline in eGFR by Inhibiting Organic Cation Transporter 2-Dependent Creatinine Secretion. | J Am Soc Nephrol | 2024 | 39159185 | PubTator, text mining | PubMed |
| Authors' Reply: Proton Pump Inhibitors May Cause a Decline in eGFR by Inhibiting Organic Cation Transporter 2-Dependent Creatinine Secretion. | J Am Soc Nephrol | 2024 | 39158981 | PubTator, text mining | PubMed |
| Three-dimensional culture of human proximal tubular epithelial cells for an in vitro evaluation of drug-induced kidney injury. | J Pharm Sci | 2024 | 39153661 | PubTator, text mining | PubMed |
| Dual mass spectrometry imaging and spatial metabolomics to investigate the metabolism and nephrotoxicity of nitidine chloride. | J Pharm Anal | 2024 | 39131801 | PubTator, text mining | PubMed |
| Unraveling cardiomyocyte responses and intercellular communication alterations in primary carnitine deficiency cardiomyopathy via single-nucleus RNA sequencing. | Heliyon | 2024 | 39091928 | PubTator, text mining | PubMed |
| Liver Fibrosis Stages Affect Organic Cation Transporter 1/2 Activities in Hepatitis C Virus-Infected Patients. | Pharmaceuticals (Basel) | 2024 | 39065716 | PubTator, text mining | PubMed |
Interactions of bosutinib with drug transporters: In vitro and In vivo inhibition of organic cation transporter 2, multidrug and toxin extrusion protein 1, and breast cancer resistance protein by bosutinib. | Biomed Pharmacother | 2024 | 39053425 | PubTator, text mining | PubMed |
| Effect of Erdafitinib on the Pharmacokinetics of Midazolam and Metformin in Patients With Advanced Solid Tumors Harboring FGFR Gene Alterations. | Clin Pharmacol Drug Dev | 2024 | 39044705 | PubTator, text mining | PubMed |
No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approaches. | Pharmacol Res Perspect | 2024 | 38988092 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6582/papers?page=5